HLA-A24 Agonist Epitopes Of MUC1-C Oncoprotein and Compositions and Methods of Use
United Kingdom
14802730.3
Filed on 2014-10-22
14802730.3
Filed on 2014-10-22
HLA-A24 Agonist Epitopes Of MUC1-C Oncoprotein and Compositions and Methods of Use
France
14802730.3
Filed on 2014-10-22
14802730.3
Filed on 2014-10-22
HLA-A24 Agonist Epitopes Of MUC1-C Oncoprotein and Compositions and Methods of Use
Spain
14802730.3
Filed on 2014-10-22
14802730.3
Filed on 2014-10-22
HLA-A24 Agonist Epitopes Of MUC1-C Oncoprotein and Compositions and Methods of Use
Germany
14802730.3
Filed on 2014-10-22
14802730.3
Filed on 2014-10-22
HLA-A24 Agonist Epitopes Of MUC1-C Oncoprotein and Compositions and Methods of Use
Switzerland
14802730.3
Filed on 2014-10-22
14802730.3
Filed on 2014-10-22
HLA-A24 Agonist Epitopes Of MUC1-C Oncoprotein and Compositions and Methods of Use
Australia
2019203443
Filed on 2019-10-22
2019203443
Filed on 2019-10-22
Methods of Producing Enriched Populations of Tumor-Reactive T Cells From Tumor
Australia
2020220209
Filed on 2020-08-21
2020220209
Filed on 2020-08-21
CD8+ T CELLS THAT ALSO EXPRESS PD-1 AND/OR TIM-3 FOR THE
TREATMENT OF CANCER
Hong Kong
42020016957.1
Filed on 2020-09-28
42020016957.1
Filed on 2020-09-28
HLA CLASS II-RESTRICTED T CELL RECEPTORS AGAINST MUTATED RAS
Hong Kong
62020019700.7
Filed on 2020-11-09
62020019700.7
Filed on 2020-11-09